Biotech entrepreneur turns talents to venture fund

The Wall Street Journal offers an in-depth look at Michael Jaharis, a noted biotech entrepreneur who recently sold Kos Pharmaceuticals to Abbott for $4.2 billion. Jaharis has launched Vatera Capital, wagering he can still pick a hot prospect. He's already invested in Aveo's fourth round and now he's looking at "dozens" of other plays to put his money to work. He should be well funded: Jaharis owned more than half of Kos when it was sold.

- read the profile from the Wall Street Journal (sub. req.)

Suggested Articles

With its $400 million Fund XII, Atlas Venture became the latest VC shop to close a major fund since the WHO officially declared COVID-19 a pandemic.

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.

Pfizer's eczema hopeful has been building its case to challenge Sanofi and Regeneron's Dupixent, but safety issues could stand in its way.